Literature DB >> 11385295

Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen.

M P Cooreman1, G Leroux-Roels, W P Paulij.   

Abstract

Hepatitis B virus surface antigen (HBsAg) vaccination has been shown to be effective in preventing hepatitis B virus (HBV) infection. The protection is based on the induction of anti-HBs antibodies against a major cluster of antigenic epitopes of HBsAg, defined as the 'a' determinant region of small HBsAg. Prophylaxis of recurrent HBV infection in patients who have undergone liver transplantation for hepatitis B-related end-stage liver disease is achieved by the administration of hepatitis B immune globulins (HBIg) derived from HBsAg-vaccinated subjects. The anti-HBs-mediated immune pressure on HBV, however, seems to go along with the emergence and/or selection of immune escape HBV mutants that enable viral persistence in spite of adequate antibody titers. These HBsAg escape mutants harbor single or double point mutations that may significantly alter the immunological characteristics of HBsAg. Most escape mutations that influence HBsAg recognition by anti-HBs antibodies are located in the second 'a' determinant loop. Notably, HBsAg with an arginine replacement for glycine at amino acid 145 is considered the quintessential immune escape mutant because it has been isolated consistently in clinical samples of HBIg-treated individuals and vaccinated infants of chronically infected mothers. Direct binding studies with monoclonal antibodies demonstrated a more dramatic impact of this mutation on anti-HBs antibody recognition, compared with other point mutations in this antigenic domain. The clinical and epidemiological significance of these emerging HBsAg mutants will be a matter of research for years to come, especially as data available so far document that these mutants are viable and infectious strains. Strategies for vaccination programs and posttransplantation prophylaxis of recurrent hepatitis need to be developed that may prevent immune escape mutant HBV from spreading and to prevent these strains from becoming dominant during the next decennia. Copyright 2001 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11385295     DOI: 10.1007/bf02256597

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  57 in total

1.  A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis.

Authors:  Xu Yang; Xiao-Peng Tang; Jian-Hua Lei; Hong-Yu Luo; Yong-Hong Zhang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  Antigenic and immunogenic changes due to mutation of s gene of HBV.

Authors:  Jun-Hui Ge; Hui-Min Liu; Jing Sun; Le-Zhi Zhang; Jin He; Yu-Li Li; Hong Liu; Yi Xu; Hong-Yu Yu; Yi-Ping Hu
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

3.  Amino acid substitutions at positions 122 and 145 of hepatitis B virus surface antigen (HBsAg) determine the antigenicity and immunogenicity of HBsAg and influence in vivo HBsAg clearance.

Authors:  Chunchen Wu; Wanyu Deng; Liu Deng; Liang Cao; Bo Qin; Songxia Li; Yun Wang; Rongjuan Pei; Dongliang Yang; Mengji Lu; Xinwen Chen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

4.  Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees.

Authors:  Pei Zhang; Mei-Ying W Yu; Richard Venable; Harvey J Alter; J Wai-Kou Shih
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-06       Impact factor: 11.205

5.  The amino Acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen.

Authors:  Yongjun Tian; Yang Xu; Zhenhua Zhang; Zhongji Meng; Li Qin; Mengji Lu; Dongliang Yang
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

6.  A novel hepatitis B virus mutant with A-to-G at nt551 in the surface antigen gene.

Authors:  Hua-Biao Chen; De-Xing Fang; Fa-Qing Li; Hui-Ying Jing; Wei-Guo Tan; Su-Qin Li
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

Authors:  William E Delaney; Huiling Yang; Christopher E Westland; Kalyan Das; Eddy Arnold; Craig S Gibbs; Michael D Miller; Shelly Xiong
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

8.  A novel nucleotide insertion in S gene of hepatitis B virus in a chronic carrier.

Authors:  Wenbin Tong; Li Sun; Jilan He; Shusen He; Fei Du
Journal:  Virol J       Date:  2010-05-22       Impact factor: 4.099

9.  Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis.

Authors:  Jean-Pierre Vartanian; Michel Henry; Agnès Marchio; Rodolphe Suspène; Marie-Ming Aynaud; Denise Guétard; Minerva Cervantes-Gonzalez; Carlo Battiston; Vincenzo Mazzaferro; Pascal Pineau; Anne Dejean; Simon Wain-Hobson
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

10.  Rapid induction of IgE responses to a worm cysteine protease during murine pre-patent schistosome infection.

Authors:  Lucia A de Oliveira Fraga; Erika W Lamb; Elizabeth C Moreno; Mitali Chatterjee; Jan Dvořák; Melaine Delcroix; Mohammed Sajid; Conor R Caffrey; Stephen J Davies
Journal:  BMC Immunol       Date:  2010-11-15       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.